| lotiglipron (PF-07081532) / Pfizer |
NCT05579977 / 2022-002834-15: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity |
|
|
| Terminated | 2 | 902 | Europe, Canada, Japan, US, RoW | PF-07081532, Placebo, Rybelsus | Pfizer, Pfizer Inc. | Diabetes Mellitus, Obesity | 07/23 | 09/23 | | |
2022-002834-15: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With T2DM and Separately PF-07081532 in People With Obesity Klinické hodnocení zkoumající hodnocený léčivý přípravek (PF-07081532) a přípravek Rybelsus u osob s diabetem 2. typu a samostatně podávaný přípravek PF-07081532 u osob s obezitou. |
|
|
| Not yet recruiting | 2 | 780 | RoW, Europe | 20mg PF-07081532-82, 60mg PF-07081532-82, 100mg PF-07081532-82, 3mg Rybelsus, 7mg Rybelsus, 14mg Rybelsus, PF-07081532-82, Tablet, Rybelsus | Pfizer Inc., Pfizer Inc. | Type 2 Diabetes Mellitus and Obesity, Type 2 Diabetes Mellitus and Obesity, Body processes [G] - Metabolic Phenomena [G03] | | | | |
NCT05677867: A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese |
|
|
| Completed | 1 | 20 | US | Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg) | Pfizer | Overweight, Obesity | 03/23 | 03/23 | | |
NCT05652647: A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men |
|
|
| Completed | 1 | 6 | Europe | Oral [14C]PF-07081532, Oral PF-07081532 and IV [14C]PF-07081532 | Pfizer | Healthy Participants | 03/23 | 03/23 | | |
NCT05478603: A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction |
|
|
| Completed | 1 | 24 | US | PF-07081532 | Pfizer | Hepatic Impairment, Healthy Volunteers | 04/23 | 04/23 | | |
NCT05745701: A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults |
|
|
| Completed | 1 | 16 | US | PF-07081532, Cyclosporine, Itraconazole | Pfizer | Healthy | 05/23 | 05/23 | | |
NCT05510245: A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction |
|
|
| Terminated | 1 | 18 | US | PF-07081532 | Pfizer | Type 2 Diabetes, Renal Impairment | 07/23 | 07/23 | | |
NCT05788328: A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants |
|
|
| Terminated | 1 | 16 | US | Dabigatran etexilate (DE), Pradaxa, Rosuvastatin, Crestor, PF-07081532, Lotiglipron | Pfizer | Healthy | 09/23 | 09/23 | | |
NCT05671653: A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range |
|
|
| Terminated | 1 | 32 | US | PF-07081532, Semaglutide, Wegovy, Ozempic | Pfizer | Obesity | 11/23 | 11/23 | | |
